Could one of the knowledgeable ones on this forum (@ longreach?) please help me to understand a statement on page 6 of the recent investor presentation.
In the target market for WiSE - patients who have a right ventricle leadless pacemaker and who need CRT can only upgrade with WiSE.
Does this mean that patients who have a right ventricle leadless pacemaker for brachycardia or defibrillation, and then develop heart failure, need CRT by the left ventricle, but that left ventricle pacemakers with a lead cannot be used? What is currently being done for these patients? Does the right ventricle leadless pacemaker have to be taken out and a right ventricle pacemaker with a lead and a left ventricle pacemaker with a lead have to be inserted?
I apologize if this is a fact that could be found by scouring EBR releases .
I took only a small , not life-changing position. For anyone who has a much larger position, have you considered factors that would prevent FDA approval?
General Investor Information EBR Systems, page-118
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.000(0.00%) |
Mkt cap ! $332.7M | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.12 | $1.08 | $127.1K | 115.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3929 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 12000 | 1 |
View Market Depth
| Last trade - 15.59pm 26/07/2024 (20 minute delay) ? |
| EBR (ASX) Chart |